Every 10-Q that Avalo Therapeutics, Inc. (AVTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics, Inc. reported a net loss of $36.4 million for the quarter ended June 30, 2026 (six‑month net loss $56.0 million), driven by higher research and development spending as its IL‑1β programs advance. Quarterly basic and diluted net loss per share was $0.83 versus $1.92 a year earlier.
Research and development expenses rose to $23.4 million in the quarter and $37.5 million year‑to‑date, including a $10.0 million development milestone accrued to Eli Lilly for the planned phase 3 trial of abdakibart. A $6.6 million fair‑value charge related to the AlmataBio milestone buyout and changes in a $18.5 million derivative liability contributed to other expense.
The company reported positive Phase 2 LOTUS data in hidradenitis suppurativa, with abdakibart achieving HiSCR75 response rates of about 42% at both doses versus 25.6% for placebo and statistically significant secondary endpoints. Following these results, Avalo completed a follow‑on offering of common stock and pre‑funded warrants, generating net proceeds of $404.9 million. As of June 30, 2026, cash, cash equivalents and investments totaled $472.2 million, and management expects this to fund operations into 2029.
Avalo Therapeutics reported a net loss of $19.6 million for the quarter ended March 31, 2026, wider than $13.1 million a year earlier, as it increased investment in its pipeline. Research and development spending rose to $14.0 million, driven by manufacturing and clinical costs for its lead IL‑1β antibody abdakibart.
The company announced positive Phase 2 LOTUS data in hidradenitis suppurativa, where abdakibart met the primary HiSCR75 endpoint at both doses, with about 42.5% combined responders versus 25.6% on placebo. On March 31, 2026, Avalo held $82.0 million in cash and short-term investments, then strengthened its balance sheet with a follow-on equity and pre-funded warrant offering generating approximately $431.3 million in gross proceeds and expected net proceeds of about $405.0 million. Management now expects current cash resources and this capital raise to fund operations into 2029 while advancing abdakibart into a registrational Phase 3 program.
Avalo Therapeutics (AVTX) reported Q3 2025 results with a net loss of $30.6 million (basic EPS $2.19 loss). The quarter showed no revenue, while operating expenses were $19.2 million, led by research and development at $13.6 million and general and administrative at $5.6 million. Other expense reflected a $12.5 million non-cash loss from the change in fair value of the derivative liability.
As of September 30, 2025, cash and cash equivalents plus short-term investments totaled $111.6 million. Year to date, operating cash outflow was $37.2 million, with additional net investing outflows of $84.1 million and financing inflows of $13.9 million. Management states existing cash and investments are expected to fund operations for at least twelve months from the filing date.
The derivative liability was $23.2 million at quarter-end, up from $8.5 million at year-end 2024. During Q3, the company raised $14.4 million net via its at-the-market program, issuing 1.7 million shares. Common shares outstanding were 17,827,635 as of September 30, 2025, and 18,133,968 as of November 3, 2025.